Home » Stocks » CLSD

Clearside Biomedical, Inc. (CLSD)

Stock Price: $2.60 USD 0.04 (1.56%)
Updated May 11, 2021 4:00 PM EDT - Market closed
After-hours: $2.67 +0.07 (2.69%) May 11, 5:40 PM
Market Cap 149.70M
Revenue (ttm) 7.89M
Net Income (ttm) -18.21M
Shares Out 46.51M
EPS (ttm) -0.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 11
Last Price $2.60
Previous Close $2.56
Change ($) 0.04
Change (%) 1.56%
Day's Open 2.40
Day's Range 2.40 - 2.69
Day's Volume 171,160
52-Week Range 1.25 - 4.53

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 day ago - Zacks Investment Research

Presentations support proprietary suprachoroidal space delivery platform and programs Presentations support proprietary suprachoroidal space delivery platform and programs

1 day ago - GlobeNewsWire

ALPHARETTA, Ga., May 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision...

1 week ago - GlobeNewsWire

ALPHARETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...

1 week ago - GlobeNewsWire

ALPHARETTA, Ga., April 05, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visi...

1 month ago - GlobeNewsWire

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -7.69% and -98.90%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the ...

2 months ago - Zacks Investment Research

- OASIS Wet AMD Phase 1/2a Trial Initiated and Cohort 1 Dosing Completed -

2 months ago - GlobeNewsWire

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

- Initial Safety Data from First Cohort Expected Mid-2021 -

2 months ago - GlobeNewsWire

ALPHARETTA, Ga., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...

2 months ago - GlobeNewsWire

ALPHARETTA, Ga., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...

2 months ago - GlobeNewsWire

ALPHARETTA, Ga., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...

2 months ago - GlobeNewsWire

- Proprietary suprachoroidal injection platform demonstrates broad applicability across multiple retinal disorders -

3 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Clearside Biomedical (CLSD).

3 months ago - Zacks Investment Research

Investors need to pay close attention to Clearside Biomedical (CLSD) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Does Clearside Biomedical, Inc. (CLSD) have what it takes to be a top stock pick for momentum investors? Let's find out.

3 months ago - Zacks Investment Research

ALPHARETTA, Ga., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...

3 months ago - GlobeNewsWire

ALPHARETTA, Ga., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...

4 months ago - GlobeNewsWire

Clearside Biomedical is aiming to make ocular gene therapy accessible. XIPERE NDA resubmission and potential approval in 2021 triggering a $15 million payment from partner Bausch Health.

4 months ago - Seeking Alpha

Two new breakout stocks for Week 1 of 2021 with better than 10% short-term upside potential. The MDA breakout picks completed 2020 up +73.4% beating the S&P 500 for the 4th consecutive year with avg ann...

Other stocks mentioned: AAPL, CAT, DIS, DOW, EIGR, INTC, JNJ ...
4 months ago - Seeking Alpha

ALPHARETTA, Ga., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visi...

5 months ago - GlobeNewsWire

ALPHARETTA, Ga., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...

6 months ago - GlobeNewsWire

Clearside Biomedical, Inc.(CLSD) CEO George Lasezkay on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

- Initiation of Phase 1/2a Trial of CLS-AX ( axitinib injectable suspension ) for Wet Age-Related Macular Degeneration Expected by Year-End 2020 - - Phase 2 Trials Using SCS Microinjector ® Ongoing by  ...

6 months ago - GlobeNewsWire

ALPHARETTA, Ga., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...

6 months ago - GlobeNewsWire

Clearside Biomedical (CLSD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

6 months ago - Zacks Investment Research

Presented the most robust aggregate dataset of suprachoroidal clinical injections demonstrating reliability and consistency of procedure Presented the most robust aggregate dataset of suprachoroidal cli...

7 months ago - GlobeNewsWire

ALPHARETTA, Ga., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve v...

8 months ago - GlobeNewsWire

ALPHARETTA, Ga., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi...

8 months ago - GlobeNewsWire

ALPHARETTA, Ga., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve v...

8 months ago - GlobeNewsWire

- New intellectual property covers suprachoroidal administration with therapeutic agents including CLS-AX and XIPERE - - New intellectual property covers suprachoroidal administration with therapeutic a...

8 months ago - GlobeNewsWire

Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 0.00% and -75.47%, respectively, for the quarter ended June 2020.

9 months ago - Zacks Investment Research

- IND Accepted by FDA for Suprachoroidal CLS-AX (axitinib injectable suspension) - - Expanded Internal Suprachoroidal Pipeline with Two New Preclinical Programs - - Engaged New Contract Manufacturer f...

9 months ago - GlobeNewsWire

- Initiation of CLS-AX Phase 1/2a Clinical Trial in Wet AMD Targeted by Year-End 2020 -

9 months ago - GlobeNewsWire

ALPHARETTA, Ga., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vis...

9 months ago - GlobeNewsWire

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

9 months ago - Zacks Investment Research

ALPHARETTA, Ga., July 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vis...

9 months ago - GlobeNewsWire

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

9 months ago - Zacks Investment Research

ALPHARETTA, Ga., July 27, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vis...

9 months ago - GlobeNewsWire

Clearside Biomedical, Inc. (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

10 months ago - Zacks Investment Research

– Preclinical CLS-AX data demonstrates a potentially long-acting therapy for neovascular age-related macular degeneration –

10 months ago - GlobeNewsWire

Clearside Biomedical Inc (CLSD) delivered earnings and revenue surprises of 22.22% and 2.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

- Management to Host Webcast and Conference Call Today at 8:30 A.M. ET -

1 year ago - GlobeNewsWire

- Pfizer veteran brings global R&D expertise to Board of Directors - - Pfizer veteran brings global R&D expertise to Board of Directors -

1 year ago - GlobeNewsWire

ALPHARETTA, Ga., April 09, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi...

1 year ago - GlobeNewsWire

Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -75.00% and -67.06%, respectively, for the quarter ended December 2019.

1 year ago - Zacks Investment Research

ALPHARETTA, Ga., March 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi...

1 year ago - GlobeNewsWire

About CLSD

Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was incorporated in... [Read more...]

Industry
Biotechnology
IPO Date
Jun 2, 2016
CEO
George Lasezkay
Employees
33
Stock Exchange
NASDAQ
Ticker Symbol
CLSD
Full Company Profile

Financial Performance

In 2020, CLSD's revenue was $7.89 million, an increase of 263.28% compared to the previous year's $2.17 million. Losses were -$18.21 million, -40.82% less than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for CLSD stock is "Buy." The 12-month stock price forecast is 6.38, which is an increase of 145.38% from the latest price.

Price Target
$6.38
(145.38% upside)
Analyst Consensus: Buy